康乃德生物医药 CNTB 深 沪
已收盘 05-15 16:00:00 美东时间
2.38
-0.100
-4.03%
华盛通- 最 高2.48
- 今 开2.42
- 成交量 11.43万股
- 最 低 2.33
- 昨 收 2.48
- 总市值 1.35亿
- 52周最高 3.82
- 市盈率 静 --
- 换手率 0.20%
- 52周最低 0.73
- 委 比 -83.21%
- 总股本 5652.13万
- 历史最高 29.274
- 量 比 0.70
- 振 幅 6.05%
- 历史最低 0.51
- 每 手 1
- 风险率 0.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Connect Biopharma Hldgs Q1 EPS $(0.34) Misses $(0.28) Estimate, Sales $169.000K
Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.28) by 21.43 percent. This is a 78.95 percent decrease over losses of $(0.19) per
05-12 21:06
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
Connect Biopharma reported Q1 2026 financial results with $46.0 million in cash and a $20.2 million private placement. Phase 2 Seabreeze STAT studies for asthma and COPD exacerbations continue as planned, with topline data expected mid-2026. Positive Phase 1 data for rademikibart showed rapid lung function improvements. The company is advancing its IL-4Rα-targeting antibody for inflammatory diseases, with a focus on acute asthma and COPD exacerba...
05-12 13:00
康乃德生物医药（CNTB.US）4月27日收盘报2.45美元/股，跌2.78%
截至2026年4月27日（美国东部时间）收盘，康乃德生物医药(CNTB.US)报收于2.45美元/股，下跌2.78%，成交量14.22万股。
04-28 06:20
Connect Biopharma Proceeds With Phase 2 Enrollment For Rademikibart Following Interim Efficacy Analysis
The independent DMC reviewed interim data based on a pre-specified analysis of treatment failure at 28 days, the rate of new exacerbations through 28 days, and the change from baseline in FEV1 following treatment of a
04-23 21:03
美股夜盘 | Turbo Energy涨24.26%，Robin Energy Ltd.涨23.44%
Turbo Energy涨24.26%；Robin Energy Ltd.涨23.44%；Indonesia Energy Corp Ltd.涨13.25%
04-02 13:01
美股夜盘 | 全球星涨16.74%，Penguin Solutions Incorporation涨10.68%
PMGC Holdings Inc.涨-48.00%；System1 Inc涨-11.69%；中国循环能源涨-9.73%
04-02 08:10
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
Connect Biopharma Hldgs Q4 EPS $(0.27) Beats $(0.30) Estimate
Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.30) by 10 percent. This is a 68.75 percent decrease over losses of $(0.16) per share
04-01 05:30
Connect Biopharma Presents Results From Phase 3 52-Week Study In Patients With AD Conducted By Simcere Pharma At 2026 AAD Annual Meeting
– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients –– Rademikibart was well tolerated with safety comparable
03-30 19:11
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
Connect Biopharma reported positive results from its Phase 1 study of IV rademikibart, showing rapid and sustained improvements in lung function (FEV1) in asthma and COPD patients. The single 300 mg dose via a 2-minute IV push demonstrated clinically meaningful FEV1 increases of ~200-400 mL as early as 15 minutes, maintained through Day 29, with no serious adverse events. The company expects to report Phase 2 data in mid-2026 and plans to discuss...
03-30 11:00
